Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 8/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ERCC5 | P28715 | 3/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762757 | 0.80 | HDAC3 (0.38) | BCHEGAAMAPT | |
| SCHEMBL28751707 | 0.76 | ALOX5 (0.44) | ALOX5BCHECD69GAAMAPT | |
| SCHEMBL28048826 | 0.76 | CTSD (0.46) | ALOX5BCHECD69GAAMAPT | |
| SCHEMBL2763863 | 0.75 | BCHE (0.45) | BCHE | |
| Thianthrene SCHEMBL30108387 | 0.73 | ALDH1A1 (0.50) | ALOX5BCHECD69GAAMAPT | |
| SCHEMBL30944663 | 0.73 | ALDH1A1 (0.50) | ALOX5BCHECD69GAAMAPT | |
| SCHEMBL2762894 | 0.73 | ALDH1A1 (0.50) | ALOX5BCHECD69GAAMAPT | |
| SCHEMBL2762893 | 0.72 | NOX1 (0.43) | ALOX5BCHEGAAMAPTKDM4E | |
| SCHEMBL9511389 | 0.71 | KDM4E (0.50) | BCHEGAAMAPTKDM4ESLC6A3 | |
| SCHEMBL11834948 | 0.70 | ALOX5 (0.40) | ALOX5BCHECD69GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485377-B9 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-1485377-B9 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-2174939-A1 | Pyranones useful as ATM inhibitors | Kudos Pharmaceuticals Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-2174939-A1 | Pyranones useful as ATM inhibitors | Kudos Pharmaceuticals Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-1485377-B1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| EP-1485377-B1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-7049313-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LTD. (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1485377-A1 | PYRANONES USEFUL AS ATM INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002492-A1 | Induce immunology response; anticancer agents | KUDOS PHARMACEUTICALS LTD (GB) | 2004-01-01 | — | — | US | disclosed |
| WO-2003070726-A1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARMACEUTICALS LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002492-A1 | Induce immunology response; anticancer agents | MYD88, IFNG, HCCS | ALOX5 1515/4885BCHE 3812/4885PPARG 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.